PHI-501, a novel and potent pan-RAF inhibitor in metastatic melanoma

被引：0
|
作者：
Kim, Namkyeong
Park, Jung Hee
Nam, Ky-Youb
Han, June H-J
Kim, Kyu-Tae
Sengupta, Sandip
Yoon, Jeong Hyeok
Sim, Taebo
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-1627
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1627
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Kinnate Biopharma Inc. sells its investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 (05)
  • [42] Simultaneous blocking of the pan-RAF and S100B pathways as a synergistic therapeutic strategy against malignant melanoma
    Wu, Ke-Jia
    Ho, Shih-Hsin
    Wu, Chun
    Wang, Hui-Min D.
    Ma, Dik-Lung
    Leung, Chung-Hang
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2021, 25 (04) : 1972 - 1981
  • [43] Combination effect of low dose Cytarabine and pan-RAF inhibitor LY3009120 in AML cells with RAS mutations
    Park, Jihyun
    Yoon, Sung-Soo
    Koh, Youngil
    CANCER RESEARCH, 2019, 79 (13)
  • [44] Phase I study of two dosing schedules of the investigational oral pan-RAF kinase inhibitor MLN2480 in patients (pts) with advanced solid tumors or melanoma
    Rasco, D. W.
    Middleton, M. R.
    Gonzalez, R.
    Corrie, P.
    Pavlick, A.
    Lorigan, P.
    Plummer, R.
    Gore, M.
    Herbert, C.
    Agarwala, S. S.
    Logan, T. F.
    Khleif, S. N.
    Papadopoulos, K. P.
    Rangachari, L.
    Suri, A.
    Xu, Q.
    Kneissl, M.
    Bozon, V.
    Olszanski, A. J.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S53 - S54
  • [45] Antitumor activity of KIN-2787, a next-generation pan-RAF inhibitor, in combination with MEK inhibition in preclinical models of human NRAS mutant melanoma.
    Miller, Nichol
    Wang, Tim Sen
    Lee, Catherine
    Severson, Paul
    Ke, Eugene
    Kobayashi, Ken
    Williams, Richard Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [46] DAY101, a potent pan-RAF inhibitor with activity in preclinical models harboring MAPK pathway alterations beyond BRAF V600E mutation.
    Venetsanakos, Eleni
    Preigh, Mike
    Hou, Jeannie
    Cox, Michael C.
    Bender, Jeremy
    Blackman, Sam C.
    CANCER RESEARCH, 2021, 81 (13)
  • [47] Nanoparticulate delivery of potent microtubule inhibitor for metastatic melanoma treatment
    Bariwal, Jitender
    Kumar, Virender
    Chen, Hao
    Bhattarai, Rajan Sharma
    Peng, Yang
    Li, Wei
    Mahato, Ram, I
    JOURNAL OF CONTROLLED RELEASE, 2019, 309 : 231 - 243
  • [48] Antitumor Effects of Pan-RAF Inhibitor LY3009120 Against Lung Cancer Cells Harboring Oncogenic BRAF Mutation
    Miyauchi, Shunsaku
    Shien, Kazuhiko
    Takeda, Tatsuaki
    Araki, Kota
    Nakata, Kentaro
    Miura, Akihiro
    Takahashi, Yuta
    Kurihara, Eisuke
    Ogoshi, Yusuke
    Namba, Kei
    Suzawa, Ken
    Yamamoto, Hiromasa
    Okazaki, Mikio
    Soh, Junichi
    Tomida, Shuta
    Yamane, Masaomi
    Sakaguchi, Masakiyo
    Toyooka, Shinichi
    ANTICANCER RESEARCH, 2020, 40 (05) : 2667 - 2673
  • [49] Cross-Species Comparison of the Pan-RAF Inhibitor LY3009120's Anti-Tumor Effects in Equine, Canine, and Human Malignant Melanoma Cell Lines
    Gao, Yu
    Packeiser, Eva-Maria
    Wendt, Sophia
    Sekora, Anett
    Cavalleri, Jessika-Maximiliane V.
    Pratscher, Barbara
    Alammar, Moosheer
    Huehns, Maja
    Brenig, Bertram
    Junghanss, Christian
    Nolte, Ingo
    Escobar, Hugo Murua
    GENES, 2024, 15 (02)
  • [50] Discovery of novel naphthalene-based diarylamides as pan-Raf kinase inhibitors with promising anti-melanoma activity: rational design, synthesis, in vitro and in silico screening
    Elkamhawy, Ahmed
    Ammar, Usama M.
    Kim, Minkyoung
    Gul, Anam Rana
    Park, Tae Jung
    Lee, Kyeong
    ARCHIVES OF PHARMACAL RESEARCH, 2025, 48 (02) : 150 - 165
12345